New drug combo for untreated aggressive B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zuberitamab) for people with newly diagnosed, aggressive B-cell lymphoma that hasn't been treated yet. The goal is to see if this combination works better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma that is newly diagnosed and has not been treated yet.
- Your lymphoma cells have a protein called CD20 on their surface (your doctor can tell you this).
- Your IPI score (a risk score for your lymphoma) is 2, 3, 4, or 5.
- You are able to do your daily activities with little or no help (ECOG score 0, 1, or 2).
- You have at least one measurable tumor (bigger than about half an inch).
- Your heart, liver, kidneys, and blood cell counts are working well enough (tests will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zanubrutinib) as a first treatment for older adults (70+) with a common type of lymphoma called DLBCL. The goal is to see if this approach is effective and well-tolerated without standard chemotherapy.
This trial tests a combination of four drugs (G-Pola-GemOx) for people with aggressive B-cell lymphoma who have not had chemotherapy before. The goal is to see if this new treatment can help control the cancer.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Hear when a new Bispecific Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.